ARCHIVES

FDA Approves NDA For Mylan’s Paclitaxel For Ovarian And Breast Cancer Treatment.

This article is from The Cancer Letter archive.

Vol. 27 No. 30 | July 27, 2001

Download PDF Visit The Full Archive

Related Articles

Revlimid Also Demonstrates Response in Mantle Cell

July 29, 2011

UPCI Recruits Shin To Lead Head & Neck Cancer Program.

April 27, 2001

NCI Spent $381.2 Million On PR From 2006 to 2012, Vastly Outspending Other NIH, FDA Units

March 1, 2013

Harold Freeman To Direct NCI Center To Reduce Cancer Health Disparities

September 15, 2000

New HIP Analysis Supports Mammography Screening Ages 40-49

September 23, 1988

AACI Remains Split On Guidelines; Terry Proposes 25 Percent Limit On Staff Investigator Salaries

January 30, 1981